The Increasing Antimicrobial Resistance of Shigella Species Among Iranian Pediatrics: A Systematic Review and Meta-Analysis Publisher Pubmed



Baharvand A¹ ; Molaeipour L² ; Alesaeidi S³ ; Shaddel R⁴ ; Mashatan N⁵ ; Amiriani T⁶ ; Kiaei Sudkolaei M⁷ ; Abbasian S⁴ ; Talib Alnaqeeb BZ⁸ ; Kouhsari E^{4, 9}
Source: Pathogens and Global Health Published:2023

Abstract

Background: Shigellosis remains one of the global causes of morbidity and mortality. However, the global emergence of antibiotic resistance has become the leading cause of treatment failure in shigellosis. This review aimed to provide an updated picture of the antimicrobial resistance rates in Shigella species in Iranian pediatrics. Methods: A comprehensive systematic search was performed on PubMed, Scopus, Embase, and Web of Science until 28 July 2021. The meta-analysis was performed by computing the pooled using a random-effects model with Stata/SE software, v.17.1. The discrepancy within articles was surveyed by the forest plot in addition to the I2 statistic. All statistical interpretations were reported on a 95% confidence interval (CI) basis. Results: Totally, of 28 eligible studies published between 2008 and 2021. The pooled prevalence rate of multidrug-resistant (MDR) was 63% (95% CI 50–76). Regarding suggested antimicrobial agents for Shigella species, the prevalence of resistance for ciprofloxacin, azithromycin, and ceftriaxone as first- and second-line treatments for shigellosis were 3%, 30%, and 28%, respectively. In contrast, resistance to cefotaxime, cefixime, and ceftazidime was 39%, 35%, and 20%. Importantly, subgroup analyses indicated that an increase in resistance rates during the periods (2008–2014, 2015–2021) was recognized for ciprofloxacin (0 % to 6%) and ceftriaxone (6% to 42%). Conclusion: Our findings revealed that ciprofloxacin is an effective drug for shigellosis in Iranian children. The substantially high prevalence estimation proposes that the first- and second-line treatments for shigellosis are the major threat to public health and active antibiotic treatment policies are essential. © 2023 Informa UK Limited, trading as Taylor & Francis Group.